(2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in ...

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD).

A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 8:00 a.m. ET ...

Analyst David Lebovitz of Citi maintained a Buy rating on Ascendis Pharma (ASND – Research Report), retaining the price target of ...

About Ascendis Pharma A/S This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts ...

Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $4,093.94 today based on a price of $135.10 for ASND at the time of writing.

COPENHAGEN - Ascendis Pharma A/S (NASDAQ:ASND) has reported encouraging outcomes from its ongoing Phase 1/2 IL-Believe Trial, evaluating TransCon IL-2 β/γ therapy for patients with melanoma who have ...

Benzinga - by Benzinga Insights, Benzinga Staff Writer. Ascendis Pharma's (NYSE:ASND) short percent of float has fallen 7.55% since its last report. The company recently reported that it has 3.46 ...

A live webcast of the fireside chat will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on ...

Investing.com - Ascendis Pharma AS reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations. Ascendis Pharma AS announced ...

Ascendis Pharma A/S (Nasdaq: ASND) shared 52-week data from the open-label extension period of its ongoing Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) showing that... Ascendis Pharma ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...